Clinical Trial Update: Efficacy and Safety of Sub-tenon Ranibizumab for Recurrent Pterygia [Phase 1]

View source ↗

Summary

Phase 1 trial evaluating the efficacy and safety of sub-tenon ranibizumab for recurrent pterygium has been completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Pterygium

Drugs mentioned

• Ranibizumab (Lucentis) (ranibizumab)

Snippet

Sponsor: University of New Mexico | Conditions: Pterygium | Phase 1 | Status: COMPLETED